Brought to you by 
GSK signs second MAGE-A3 collaboration with Abbott Molecular
03 Nov 2011
Executive Summary
In their second personalized medicine alliance in less than a year, Abbott Molecular and GlaxoSmithKline are teaming up to develop and market a companion diagnostic for GSK's Phase III skin cancer therapeutic. The real-time PCR test will run on Abbott's m2000 automated molecular instrument used for DNA and RNA testing.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK signs second MAGE-A3 collaboration with Abbott Molecular
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice